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Purpose of the study
To evaluate the efficacy of raltegravir (RAL) and etravirine
(ETV) in addition to a background optimised treatment in
patients (pts) with persistent viremia while on darunavir
(DRV) and multidrug resistant virus.
Methods
Prospective, pilot, open-label, single arm study evaluating
pts with at least 3-drug class exposure, plasma HIV-RNA
(VL) >1000 c/ml while on a DRV-containing regimen. Pts
were given RAL and ETV in addition to optimized back-
ground therapy (OBT). Primary end-point was the pro-
portion of pts with a VL<40 c/ml at week 24.
Summary of results
Overall, 20 pts were enrolled. Baseline characteristics were
as follows: median duration of prior ARV therapy 13 years
[range: 6–20], median VL of 4.6 log10 [3.36–5.56], and
median CD4 count of 254 cells/mm3 [63–833]. Eleven
pts (55%) had prior enfuvirtide and four prior foscarnet.
Excluding RAL and ETV, GSS was 0 for two pts, one for 11
(58%) pts, two for five (25%) pts and 3 for one pt. Four-
teen pts (74%) had a virus with 1 NNRTI resistance muta-
tion (median: 1 [0–3]), 14 (73%) were resistant to DRV,
four (21%) had intermediate DRV sensitivity. The median
number of antiretroviral drugs in the OBR was five [3–7],
five (25%) received atazanavir and nine (45%) enfuvir-
tide.
At week 24, the proportion of patients with VL< 40 c/ml
was 65% and the proportion <400 copies/ml 100%. The
median decrease in viral load was -2.56 log10 [-3.78 – -
1.01] at week 4, -2.87 log10 [-3.78 – -1.01] at week 12 and
-2.90 log10 [-3.78 – -1.76] at week 24. The median
increase in CD4 was + 80 [-29 – +485] cells/mm3 at week
24. At week 4, the median RAL Cmin in nine pts was 134
ng/ml [44–379], ETV: 374 ng/ml [86–785] and DRV:
3487 ng/ml [1442–4603]. Resistance testing was success-
ful in 3/7 patients between 40 and 400 c/ml: none had
RAL-associated mutations.
Conclusion
An unexpectedly high rate of virological success was
observed in this pilot study of patients with very limited
treatment options except RAL and ETV while failing daru-
navir.
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